Claims for Patent: 6,042,835

Summary for Patent: 6,042,835

Title:	Prototype FelV isolates for use in disease models and vaccines
Abstract:	Molecular clones of feline leukemia virus isolates that encode (a) a prototype highly infectious, minimally pathogenic virus, (b) a variant genome that is replication-defective and associated with a fatal immunodeficiency in cats similar to AIDS (FAIDS) or (c) a chimeric genome that is replication-competent and induces FAIDS. These molecular clones may be used to generate cell lines producing infectious virus which is useful in the preparation of vaccines or in the generation of viremia or disease challenge systems.
Inventor(s):	Hoover; Edward A. (Fort Collins, CO), Mullins; James I. (Brookline, MA)
Assignee:	Colorado State University Research Foundation (Fort Collins, CO) Harvard University (Cambridge, MA)
Application Number:	08/233,004
Patent Claims:	1. A method of producing a FeLV vaccine, comprising: transfecting a mammalian host cell with a recombinant plasmid capable of directing the expression of the proviral genome of a FeLV-A subtype, said plasmid comprising a DNA sequence encoding the proviral genome of a FeLV-A subtype; growing said host cell in an appropriate medium; harvesting the FeLV-A subtype; and inactivating the FeLV-A subtype. 2. The method of claim 1 including, after the step of inactivating, concentrating the FeLV-A subtype to achieve an antigenic mass. 3. The method of claim 1 wherein the step of inactivating comprises exposing the FeLV-A subtype to formalin, beta-propriolactone or binary ethyleneimine under conditions and for a time sufficient to inactivate the FeLV-A subtype. 4. The method of claim 1 wherein the DNA sequence is derived from a clone selected from the group consisting of clones 61E, EECC and naturally occurring variants of Clones 61E or EECC. 5. A method of producing a FeLV vaccine, comprising: cotransfecting a mammalian host cell with a recombinant plasmid capable of directing the expression of the proviral genome of a FeLV-A subtype, said plasmid comprising a DNA sequence derived from the clone 61C or a naturally occurring variant thereof, and a DNA sequence derived from a FeLV-A clone which is replication competent; growing said host cell in an appropriate medium; harvesting the FeLV-A subtype; and inactivating the FeLV-A subtype. 6. The method of claim 5 wherein the FeLV clone which is replication competent is clone 61E or a naturally occurring variant thereof. 7. The method of claim 5 including, after the step of inactivating, concentrating the FeLV-A subtype to achieve an antigenic mass. 8. A method of producing a FeLV vaccine, comprising: infecting a mammalian host cell with a replication competent virus of the FeLV-A subtype; growing said host cell in an appropriate medium; harvesting the FeLV-A subtype; and inactivating the FeLV-A subtype. 9. The method of claim 8 wherein the FeLV-A subtype is encoded by clone 61E, clone EECC or a naturally occurring variant of Clone 61E or Clone EECC. 10. The method of claim 8 wherein the FeLV-A subtype is encoded by a DNA sequence derived from clone 61E or a naturally occurring variant thereof, in combination with a DNA sequence derived from clone 61C or a naturally occurring variant thereof. 11. A method for protecting a feline host from FeLV infection, comprising: administering to a feline host an immunogenically effective amount of a composition comprising an inactivated FeLV-A subtype in combination with a physiologically acceptable carrier or diluent. 12. The method of claim 11 wherein the carrier or diluent is selected from the group consisting of sterile water and phosphate-buffered saline. 13. The method of claim 11 wherein the composition includes a suitable adjuvant. 14. The method of claim 13 wherein the adjuvant is selected from the group consisting of RIBI adjuvant, oil adjuvants, particulate adjuvants and general immune stimulating adjuvants. 15. The method of claim 13 wherein the adjuvant is Freund's adjuvant or incomplete Freund's adjuvant. 16. The method of claim 11 wherein the physiologically acceptable carrier or diluent comprises cell-free supernatant derived from FeLV-A subtype-producing cells. 17. The method of claim 16 wherein the physiologically acceptable carrier or diluent further includes whole cell lysates of FeLV-A subtype-producing cells. 18. The method of claim 11 wherein the composition includes approximately 1-5.times.10.sup.5 focus-forming units of inactivated FeLV-A subtype per kilogram of feline host weight. 19. The method of claim 11 wherein the composition is administered subcutaneously, intramuscularly, intraperitoneally or intravenously. 20. A vaccine against FeLV-induced disease, comprising an inactivated FeLV-A subtype in combination with a suitable adjuvant. 21. The vaccine of claim 20 wherein the adjuvant is selected from the group consisting of RIBI, oil adjuvants, particulate adjuvants and general immune stimulating adjuvants. 22. The vaccine of claim 20 wherein the adjuvant is Freund's adjuvant or incomplete Freund's adjuvant. 23. The vaccine of claim 20 wherein the FeLV-A subtype is encoded by a DNA sequence derived from clone EECC or a naturally occurring variant thereof. 24. The vaccine of claim 20 wherein the FeLV-A subtype is encoded by a DNA sequence derived from clone 61E or a naturally occurring variant thereof. 25. A vaccine against FeLV-induced disease, comprising a FeLV-A subtype encoded by a DNA sequence derived from clone 61E or a naturally occurring variant thereof, in combination with a FeLV-A subtype encoded by a DNA sequence derived from clone 61C or a naturally occurring variant thereof, and a physiologically acceptable carrier or diluent.

Details for Patent 6,042,835

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2017-03-28